Fujian Aonong Biological Technology Group Incorporation Limited (SHA:603363)
China · Delayed Price · Currency is CNY 2.990
-0.100 (-3.24%)
Sep 14, 2026, 3:00 PM CST
SHA:603363 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 9,011 | 8,447 | 8,731 | 19,432 | 21,581 | 18,013 |
Other Revenue | 27.79 | 27.79 | 31.41 | 25.21 | 31.93 | 25.56 |
| 9,039 | 8,475 | 8,763 | 19,458 | 21,613 | 18,038 | |
Revenue Growth | 12.09% | -3.29% | -54.96% | -9.97% | 19.82% | 56.62% |
Cost of Revenue | 8,773 | 7,956 | 8,367 | 20,767 | 20,956 | 18,209 |
Gross Profit | 265.65 | 518.85 | 395.6 | -1,309 | 657.28 | -170.49 |
Selling, General & Admin | 559.9 | 529.29 | 1,129 | 1,071 | 1,073 | 944.98 |
Research & Development | 55.28 | 49.75 | 54.47 | 148.86 | 161.67 | 113.88 |
Other Operating Expenses | 31.84 | 26.71 | 6.05 | 24.6 | 25.76 | -2.41 |
Operating Expenses | 670.01 | 628.75 | 1,245 | 1,291 | 1,285 | 1,101 |
Operating Income | -404.37 | -109.9 | -849.59 | -2,600 | -628.17 | -1,272 |
Interest Expense | -143.19 | -143.19 | -650.95 | -549.99 | -505.83 | -418.77 |
Interest & Investment Income | 191.43 | 522.13 | 2,043 | 5.19 | 5.94 | 3.76 |
Currency Exchange Gain (Loss) | 0.08 | 0.08 | -0.1 | -1.41 | -6.85 | -0.34 |
Other Non Operating Income (Expenses) | -152.72 | -157.45 | -53.81 | -52.18 | -75.77 | -20.85 |
EBT Excluding Unusual Items | -508.77 | 111.67 | 488.56 | -3,198 | -1,211 | -1,708 |
Impairment of Goodwill | -27.47 | -27.47 | -35.39 | -34.66 | -36.51 | -12.14 |
Gain (Loss) on Sale of Investments | -4.59 | -3.98 | -30.32 | -4.07 | -119.76 | -68.86 |
Gain (Loss) on Sale of Assets | -5.85 | -3.22 | 5.59 | -49.74 | -9.41 | -25.09 |
Asset Writedown | -15.75 | -15.75 | -98.51 | -424.3 | -2.76 | -7.63 |
Other Unusual Items | 44.09 | 44.09 | -245.43 | 29.37 | 84.1 | - |
Pretax Income | -518.34 | 105.34 | 84.49 | -3,682 | -1,295 | -1,822 |
Income Tax Expense | 39.35 | 15.93 | 21.4 | 87.05 | -69.21 | 29.34 |
Earnings From Continuing Operations | -557.69 | 89.41 | 63.09 | -3,769 | -1,226 | -1,851 |
Minority Interest in Earnings | 84.68 | -11.79 | 516.25 | 117.86 | 187.46 | 331.05 |
Net Income | -473.01 | 77.62 | 579.35 | -3,651 | -1,038 | -1,520 |
Net Income to Common | -473.01 | 77.62 | 579.35 | -3,651 | -1,038 | -1,520 |
Net Income Growth | - | -86.60% | - | - | - | - |
Shares Outstanding (Basic) | 2,655 | 2,587 | 865 | 867 | 775 | 650 |
Shares Outstanding (Diluted) | 2,655 | 2,587 | 865 | 867 | 775 | 650 |
Shares Change | 54.54% | 199.23% | -0.29% | 11.91% | 19.30% | 3.15% |
EPS (Basic) | -0.18 | 0.03 | 0.67 | -4.21 | -1.34 | -2.34 |
EPS (Diluted) | -0.18 | 0.03 | 0.67 | -4.21 | -1.34 | -2.34 |
EPS Growth | - | -95.52% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -27.99 | -79.95 | -379.46 | 472.23 | -835.31 | -2,184 |
Free Cash Flow Per Share | -0.01 | -0.03 | -0.44 | 0.55 | -1.08 | -3.36 |
Gross Margin | 2.94% | 6.12% | 4.52% | -6.73% | 3.04% | -0.95% |
Operating Margin | -4.47% | -1.30% | -9.70% | -13.36% | -2.91% | -7.05% |
Profit Margin | -5.23% | 0.92% | 6.61% | -18.76% | -4.80% | -8.43% |
Free Cash Flow Margin | -0.31% | -0.94% | -4.33% | 2.43% | -3.86% | -12.11% |
EBITDA | 2.07 | 298.69 | -248.22 | -1,776 | 232.72 | -574.94 |
EBITDA Margin | 0.02% | 3.52% | -2.83% | -9.13% | 1.08% | -3.19% |
D&A For EBITDA | 406.44 | 408.59 | 601.37 | 823.53 | 860.9 | 696.72 |
EBIT | -404.37 | -109.9 | -849.59 | -2,600 | -628.17 | -1,272 |
EBIT Margin | -4.47% | -1.30% | -9.70% | -13.36% | -2.91% | -7.05% |
Effective Tax Rate | - | 15.12% | 25.33% | - | - | - |
Revenue as Reported | 8,475 | 8,475 | 8,763 | 19,458 | 21,613 | 18,038 |